respiratory syncytial virus

News

Beyfortus now has a direct rival after FDA OK for Enflonsia

MSD could soon enter the US market for drugs used to protect infants from RSV infections, setting up a rivalry with AstraZeneca/Sanofi's Beyfortus.

News

Sanofi starts shipping RSV drug early as rival nears market

As an FDA decision nears from a rival MSD drug, Sanofi is speeding up the rollout of RSV antibody Beyfortus to get ahead of this year's season.

News

There's good news for RSV jab firms at delayed ACIP meeting

GSK and Pfizer could see a resurgence in sales of their RSV vaccines if new recommendations at a CDC expert meeting are confirmed by agency leaders.

News

GSK rides out vaccine sales weakness with cancer, HIV gains

Despite a steep fall-off in sales of RSV vaccine Arexvy last year, GSK has raised its long-term sales forecast to £40 billion in 2031.

News

Adult holding the hand of a newborn baby

MSD eyes June verdict for paediatric RSV antibody

The FDA has started a review of MSD's RSV antibody clesrovimab, a potential rival to Beyfortus, with a verdict due in the middle of next year.

News

Alarm bell rings for GSK as US policy dents RSV jab sales

Sales of GSK's respiratory syncytial virus (RSV) vaccine Arexvy slumped 72% in the third quarter of this year, as narrower recommendations on its use in the US started to have an effect.

Beyfortus now has a direct rival after FDA OK for Enflonsia

Sanofi starts shipping RSV drug early as rival nears market

There's good news for RSV jab firms at delayed ACIP meeting

GSK rides out vaccine sales weakness with cancer, HIV gains

MSD eyes June verdict for paediatric RSV antibody

Alarm bell rings for GSK as US policy dents RSV jab sales

LSX2026: On promise and patience, with Hans Schambye

Using AI-driven synthetic personas to take your insights fur...

respiratory syncytial virus

Editor's Picks